Paris and Tampa, Fla., Jan. 13, 2026 — SafeHeal®, a clinical-stage medical device innovator in colorectal surgery, announced the successful first patient enrollment in its pivotal SAFE-3CV Investigational Device Exemption (IDE) study, evaluating Colovac®, an endoluminal bypass sheath designed to protect colorectal anastomoses. The SAFE-3CV study represents the final clinical phase toward U.S. FDA marketing approval and will also support EU post-market surveillance, enrolling up to 252 patients across as many as 20 U.S. and European sites. The milestone signals strong momentum for a technology positioned to transform recovery after colorectal surgery.
Science Significance
Scientifically, Colovac® addresses a long-standing challenge in colorectal surgery: protecting the anastomotic site during the critical healing window. The device functions as a temporary endoluminal bypass, reducing fecal contact with the healing tissue and thereby mitigating leakage and related complications. Unlike conventional diverting ostomies, Colovac® is placed endoluminally and removed endoscopically after approximately 10 days, aligning with natural tissue repair processes. Prior clinical studies conducted across the U.S., Europe, and Asia demonstrated favorable safety and efficacy, supporting the hypothesis that mechanical diversion can be achieved without creating a stoma. SAFE-3CV is designed to generate robust comparative evidence against standard-of-care ostomy procedures.
Regulatory Significance
From a regulatory perspective, SAFE-3CV is a pivotal IDE study, reflecting the highest level of FDA oversight for investigational medical devices. The trial is structured to meet Good Clinical Practice (GCP) requirements and will provide the primary clinical evidence package for FDA premarket review. Importantly, Colovac® has already received European Union marketing approval under EU MDR 2017/745, validating its safety and performance under stringent regulatory standards. The device has also been granted FDA Breakthrough Device designation, enabling expedited review and enhanced regulatory engagement. Successful completion of SAFE-3CV is the final step toward U.S. commercialization.
Business Significance
Advertisement
For SafeHeal®, the launch of SAFE-3CV marks a critical value-inflection point. Transitioning into a pivotal IDE study positions the company closer to U.S. market entry in a large and clinically significant surgical segment. Diverting ostomies are widely used in colorectal resections, yet they carry substantial downstream costs related to secondary surgeries, prolonged hospital stays, and complications. By offering a less invasive alternative, Colovac® has the potential to deliver both clinical and economic value to hospitals and healthcare systems. The study also strengthens SafeHeal’s standing as a MedTech innovator capable of executing complex, multinational clinical programs.
Patients’ Significance
For patients, the potential benefits of Colovac® are substantial. Temporary diverting ostomies often impose a significant physical, emotional, and social burden, including lifestyle disruption, stigma, and the risk of permanent stoma formation. Many patients require a second surgical procedure to reverse the ostomy, extending recovery timelines and increasing complication risk. Colovac® aims to eliminate the need for a stoma in most patients, enabling faster recovery, fewer procedures, and improved quality of life. By reducing both physical complications and psychological stress, the technology addresses outcomes that matter most to patients undergoing colorectal surgery.
Policy Significance
At a policy level, SAFE-3CV aligns with broader healthcare objectives focused on innovation, patient-centered care, and cost containment. Regulatory agencies increasingly support technologies that can reduce complications, shorten hospital stays, and improve surgical outcomes. The FDA’s Breakthrough Device designation underscores the policy priority of accelerating access to transformative medical technologies for serious conditions such as colorectal cancer. Additionally, the study contributes to the growing body of evidence supporting less invasive surgical pathways, which may influence future clinical guidelines and reimbursement frameworks.
The successful launch of the SAFE-3CV IDE study represents a pivotal advancement for SafeHeal® and the broader field of colorectal surgery. By combining strong scientific rationale, rigorous regulatory design, and a clear patient-centered value proposition, Colovac® is positioned to redefine standards of care for anastomosis protection. As SAFE-3CV progresses toward completion in 2026, its outcomes will be closely watched by regulators, clinicians, and health systems seeking innovative, GxP-compliant solutions that improve recovery and quality of life after colorectal surgery.
Source: SafeHeal press release
